Olathe, Kan., September 1, 2015 - ELIAS Animal Health, a clinical stage development company advancing novel targeted T cell-based immunotherapy for the treatment of cancer in companion animals, today announced it has filled the remaining appointments to the company’s scientific advisory board with the additions of Ronald Schultz, PhD, and Noe Reyes, DVM. They join board chair Kevin Schultz, DVM, PhD, and Ralph Richardson, DVM, on the advisory board, which is tasked with offering strategic guidance on the advancement of therapies in development and exploring new therapeutic areas in which the company’s technology would be applicable. Dr. Ron Schultz is a recognized leader on veterinary vaccines, virology and immunology. He currently serves as professor and chair of the Department of Pathobiological Sciences at the School of Veterinary Medicine at the University of Wisconsin-Madison. His primary emphasis of research focuses on the pathogenesis of viral infections in large and companion animals. [...]

Olathe, Kan., Aug. 4, 2015 - ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, today announced the initiation of a clinical trial to determine the safety and efficacy of ECI-OSA-11, the company’s T cell-based immunotherapy for the treatment of osteosarcoma, a common form of canine cancer for which there is no cure. This fully-funded clinical trial will enroll dogs that have been diagnosed with osteosarcoma, but have not yet been treated for their cancer. The trial will be conducted at the University of Missouri, Columbia College of Veterinary Medicine. ECI-OSA-11 is a form of immunotherapy that involves treating the patient with its own cancer-specific “killer” T cells. The patient will have surgery to remove their osteosarcoma and then will be treated with ECI-OSA-11 to eliminate cancer cells that remain following surgery. The objective of this clinical trial is to determine whether ECI-OSA-11 [...]